|Bid||0.00 x 1200|
|Ask||0.00 x 800|
|Day's range||79.17 - 79.80|
|52-week range||55.21 - 82.08|
|Beta (5Y monthly)||0.73|
|PE ratio (TTM)||111.69|
|Forward dividend & yield||0.23 (0.30%)|
|Ex-dividend date||10 May 2023|
|1y target est||91.27|
Here is how Alcon (ALC) and Swedish Orphan Biovitrum (BIOVF) have performed compared to their sector so far this year.
By buying an index fund, investors can approximate the average market return. But if you buy good businesses at...
GENEVA, May 22, 2023--Alcon Advances Company’s Social Impact Through Global Volunteerism
For Alcon (ALC), in terms of end market, Surgical global cataract procedure growth varies significantly by region.
Alcon (ALC) Q1 revenues were driven by strong consumables and equipment sales.
Baird upgraded Alcon (NYSE:ALC) to Outperform from Neutral and raised its price target to $90.00 from $75.00 following Q1 earnings. Shares jumped more than 7% pre-market today after the company reported its Q1 results, with EPS of $0.70 and revenue of $2.3 billion beating the consensus estimates. BTIG upgraded NeoGenomics (NASDAQ:NEO) to Buy from Neutral with a price target of $25.00, noting it was impressed by the change in underlying growth at the company since the new management team has taken over.
GENEVA, May 09, 2023--Alcon Reports First Quarter 2023 Results
FORT WORTH, Texas, May 06, 2023--New Head-to-Head Data Show Clareon Monofocal IOLs and TECNIS Eyhance Monofocal IOLs Provide Similar Range of Vision
GENEVA, May 05, 2023--Alcon Announces Results of 2023 Annual General Meeting
FORT WORTH, Texas, May 01, 2023--Alcon Announces Largest-Ever Scientific Presence at ASCRS 2023 and Expands Image-Guided Connectivity
Amid persistent supply-chain headwinds, Alcon's (ALC) first-quarter top-line results are likely to reflect the commercial execution of new product launches across its segments and contributions from strategic alliances.
Alcon (VTX:ALC) has had a rough three months with its share price down 5.8%. However, stock prices are usually driven...
Alcon (ALC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
GENEVA, March 29, 2023--Alcon Publishes Agenda for 2023 Annual General Meeting
GENEVA, March 23, 2023--Alcon’s "The Lens" Interactive Compliance Training Experience Receives Coveted Anthem Award
GENEVA, March 20, 2023--Alcon to Host 2023 Capital Markets Day
Alcon (ALC) showcases its reusable toric lens and dry eye/ocular health offerings at the SECO International Meeting 2023 in Atlanta.
FORT WORTH, March 01, 2023--Alcon to Debut TOTAL30 for Astigmatism, Dry Eye and Ocular Health Innovations at SECO 2023
Alcon (ALC) reports impressive CER growth in net sales across all segments in the fourth quarter amid a challenging macroeconomic environment.
GENEVA, February 27, 2023--Alcon Reports Fourth Quarter and Full Year 2022 Results
Alcon Vision LLC will pay Johnson & Johnson's J&J Surgical Vision Inc $199 million to settle legal battles over intellectual property related to the companies' laser eye-surgery devices, Alcon said in a press release on Sunday. Alcon said the one-time payment would resolve "various worldwide intellectual property disputes" and that the companies had reached a cross-licensing agreement. Representatives for Johnson & Johnson did not immediately respond to a request for comment Monday on the settlement.
GENEVA, February 13, 2023--Alcon Announces Settlement of Litigation Related to Femtosecond Laser Assisted Cataract Surgery Devices
TORONTO, February 02, 2023--TOTAL30® for Astigmatism and DAILIES TOTAL1® for Astigmatism launches in Canada.
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...
Alcon's (ALC) Surgical franchise continues to lead the market with its portfolio of advanced technology, intraocular lenses, a substantial installed base of equipment and a growing consumable base.